Perioperative serum levels of tumour-necrosis-factor alpha (TNF-α), IL- 1β, IL-6, IL-10 and soluble IL-2 receptor in patients undergoing cardiac surgery with cardiopulmonary bypass without and with correction for haemodilution

Clinical and Experimental Immunology

Volumn 118, Issue 2, 1999, Pages 242-246

  Roth Isigkeit, A ^a   Borstel, T V ^a   Seyfarth, M ^a   Schmucker, P ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Cardiac surgery; Cardiopulmonary bypass; Cytokine; Haematocrit; Haemodilution; IL 1 ; IL 10; IL 6; sIL 2R; Tumour necrosis factor alpha

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CORONARY ARTERY BYPASS GRAFT; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HEART SURGERY; HEMATOCRIT; HEMODILUTION; HUMAN; HUMAN TISSUE; INFLAMMATION; MALE; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; HEMODILUTION; HUMANS; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKIN-6; INTRAOPERATIVE CARE; MALE; MIDDLE AGED; POSTOPERATIVE CARE; PREOPERATIVE CARE; RECEPTORS, INTERLEUKIN-2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0005605308     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.01050.x     Document Type: Article

References (25)

1. 1 Hall RI, Smith MS, Rocker G. The systemic inflammatory response to cardiopulmonary bypass: pathophysiological, therapeutic, and pharmacological considerations. Anesth Analg 1997; 85:766-82.
2. 2 Herskowitz A, Mangano DT. Inflammatory cascade. A final common pathway for perioperative injury? Anesthesiology 1996; 85:957-60.
3. 3 Blackwell TS, Christman JW, Sepsis and cytokines. Br J Anaesth 1996; 77:110-7.
4. 4 McBride WT, Armstrong MA, McBride SJ. Immunomodulation: an important concept in modern anaesthesia. Anaesthesia 1996; 51:465-73.
5. 5 Marti F, Munoz J, Peiro M et al. Higher cytotoxic activity and increased levels of IL-1β, IL-6, and TNF-α in patients undergoing cardiopulmonary bypass. Am J Hematol 1995; 49:237-9.
6. 6 Abe K, Nishimura M, Sakakibara T. Interleukin-6 and tumour necrosis factor during cardiopulmonary bypass. Can J Anaesth 1994; 41:876-7.
7. 7 Westaby S. Organ dysfunction after cardiopulmonary bypass. A systemic inflammatory reaction initiated by the extracorporeal circuit. Intens Care Med 1987; 13:89-95.
8. 8 Butler J, Pillai R, Rocker GM, Westaby S, Parker D, Shale DJ. Effect of cardiopulmonary bypass on systemic release of neutrophil elastase and tumor necrosis factor. J Thorac Cardiovasc Surg 1993; 105:25-30.
9. 9 Liam BL, Plöchl W, Cook DJ, Orszulak TA, Daly RC. Hemodilution and whole body oxygen balance during normothermic cardiopulmonary bypass in dogs. J Thorac Cardiovasc Surg 1998; 115:1203-8.
10. 10 Taylor KM, Bain WH, Jones JV, Walker MS. The effect of hemodilution on plasma levels of cortisol and free cortisol. J Thorac Cardiovasc Surg 1976; 72:57-61.
11. 11 Inaba H, Kochi A, Yorozu S. Suppression by methylprednisolone of augmented plasma endotoxin-like activity and interleukin-6 during cardiopulmonary bypass. Br J Anaesth 1994; 72:348-50.
12. 12 Frering H, Philip I, Dehoux M, Rolland C, Langlois JM, Desmonts JM. Circulating cytokines in patients undergoing normothermic cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994; 108:636-41.
13. 13 Roth-Isigkeit A, Schwarzenberger J, von Borstel T et al. Perioperative cytokine release during coronary artery bypass grafting in patients of different ages. Clin Exp Immunol 1998; 114:26-32.
14. 14 Taggart DP, Fraser WD, Fell GS, Wheatley DJ, Shenkin A. Plasma albumin and haemodilution: the problem of interpretation in sequential studies. Ann Clin Biochem 1989; 26:132-6.
15. 15 Ide H, Kakiuchi T, Furuta N et al. The effect of cardiopulmonary bypass on T cells and their subpopulations. Ann Thorac Surg 1987; 44:277-82.
16. 16 Misoph M, Babin-Ebell J. Interindividual variations in cytokine levels following cardiopulmonary bypass. Heart Vessels 1997; 12:119-27.
17. 17 Kaltin RE, Engelman RM, Rousou JA et al. Induction of interleukin-8 expression during cardiopulmonary bypass. Circulation 1993; 8811:401-6.
18. 18 Sawa Y, Shimazaki Y, Kadoba K et al. Attenuation of cardiopulmonary bypass-derived inflammatory reactions reduces myocardial reperfusion injury in cardiac operations. J Thorac Cardiovasc Surg 1996; 111:29-35.
19. 19 Hennein MA, Ebba H, Rodriguez JL et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg 1994; 108:626-35.
20. 20 Knudsen F, Andersen LW. Immunological aspects of cardiopulmonary bypass. J Cardiothorac Anesth 1990; 4:245-58.
21. 21 Butler J, Chong GL, Baigrie RJ, Pillai R, Westaby S, Rocker GM. Cytokine responses to cardiopulmonary bypass with membrane and bubble oxygenation. Ann Thorac Surg 1992; 53:833-8.
22. 22 Kawamura T, Wakusawa R, Okada K, Inada S. Elevation of cytokines during open heart surgery with cardiopulmonary bypass: participation of intedeukin 8 and 6 in reperfusion injury. Can J Anaesth 1993; 40:1016-21.
23. 23 Almdahl SM, Waage A, Ivert T, Vaage J. Release of bioactive interleukin 6 but not of tumour necrosis factor-α after elective cardiopulmonary bypass. Perfusion 1993; 8:233-8.
24. 24 Cruickshank AM, Fraser WD, Burns HJ, Van Damme J, Shenkin A. Response of serum interleukin-6 in patients undergoing elective surgery of varying severity. Clin Sci 1990; 79:161-5.
25. 25 Udelsman R, Holbrook NJ. Endocrine and molecular responses to surgical stress. Curr Prob Surg 1994; 31:653-720.